Every 8-K that Inogen Inc (INGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INGN filings page.
Inogen (INGN) agreed to sell Rotech Healthcare substantially all assets used solely in its U.S. oxygen rental business, including specified inventory and related patient records, for estimated consideration of up to approximately $24.8 million. The amount is subject to post-closing reconciliation and payable in six installments. Closing is subject to customary conditions and expected in the fourth quarter of 2026.
Inogen also signed a long-term product supply agreement with Rotech. The share repurchase amendment is effective only upon closing; it would increase the total authorization from $30.0 million to $45.0 million, including prior repurchases, and extend the program through June 30, 2028. Rental Business revenue was $24.3 million in the first half of 2026, down 9.8% year over year. Inogen expects to present the business as discontinued operations beginning with third-quarter 2026 results, subject to its final accounting analysis.
Inogen, Inc. reported second quarter 2026 results with revenue of $95.1 million, up 3.0% year-over-year, and raised full-year adjusted EBITDA guidance to approximately $4.0 million, representing a 48.1% increase from 2025 adjusted EBITDA of $2.7 million.
International sales were $41.3 million, up 14.8%, while U.S. sales and rentals declined, and total gross margin improved to 45.5% from 44.8% a year earlier. GAAP net loss was $3.9 million compared with $4.2 million, and adjusted EBITDA increased to $2.4 million from $2.1 million. The company generated $2.9 million of operating cash flow in the quarter and ended June 30, 2026 with $106.8 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, after repurchasing 1,145,150 shares for $7.5 million in the first half.
Operationally, Inogen reported publication of its QuOTE assessment tool for Long-Term Oxygen Therapy, launch of the Rove 6 portable oxygen concentrator in Canada, completion of Last Patient Last Visit for the Simeox H SCOPE Study in China, and the appointment of a new Chief Operating Officer.
Inogen, Inc. is creating a new Chief Operating Officer role and has appointed Andy Reding, effective July 6, 2026. He will oversee revenue, operations, and cross-functional execution as the company pursues new products and geographic expansion in respiratory care.
Reding’s employment agreement provides a $500,000 annual base salary, a target bonus equal to 70% of salary, and a $100,000 cash sign-on bonus, partially repayable if he departs under certain conditions within two years. Inogen will also reimburse $2,500 of his legal fees related to the agreement.
As an equity inducement, Reding will receive 130,000 time-based RSUs, vesting in three equal annual installments, granted outside existing equity plans under Nasdaq Listing Rule 5635(c)(4). If he is terminated without cause or resigns for good reason, he may receive salary continuation and subsidized medical benefits for 12 months, or 24 months if this occurs around a change of control, subject to a release of claims and other conditions.
Inogen, Inc. reported results of its annual stockholder meeting and changes to its equity compensation plan. Stockholders approved an Amended and Restated 2023 Equity Incentive Plan that increases the shares of common stock available for awards by an additional 750,000 shares, effective upon approval.
Two Class III directors, Glenn Boehnlein and Mira Sahney, were re-elected, and Deloitte & Touche LLP was ratified as independent auditor for the year ending December 31, 2026. Stockholders approved executive compensation on an advisory basis and the equity plan, while an amendment to declassify the board was not approved. About 20,844,941 of 27,324,616 entitled shares were represented, a turnout of approximately 76.28%.
Inogen, Inc. reported first quarter 2026 revenue of $85.1 million, up 3.4% from a year earlier, driven by higher international portable oxygen concentrator demand and favorable foreign exchange, which offset lower U.S. sales and rentals. Total gross margin edged up to 44.5%, and adjusted gross margin reached 44.7%.
The company posted a GAAP net loss of $8.3 million (basic and diluted loss of $0.30 per share) versus a $6.2 million loss last year, while adjusted net loss widened to $4.0 million. Adjusted EBITDA was a loss of $1.4 million compared with slightly positive $0.04 million, reflecting increased research and development investments.
Inogen ended the quarter with $111.5 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, and repurchased 298,100 shares for $1.9 million under a $30.0 million authorization. The company guided second quarter 2026 revenue to $94–$97 million and reiterated full-year 2026 revenue of $366–$373 million, about 6.0% growth at the midpoint, and remains focused on improving adjusted EBITDA.
Inogen, Inc. reported a governance update centered on a new director and a cooperation agreement with a significant shareholder group. The board appointed medical device veteran Vafa Jamali as a Class I independent director, effective on the earlier of the 2026 annual meeting or June 15, 2026, with his term running to the 2027 annual meeting. He will also join the Audit and Compliance Committees and be paid annual cash fees of $45,000 for board service, $10,000 for the Audit Committee, and $5,000 for the Compliance Committee, plus an initial RSU grant valued at $180,000. Inogen entered into a Cooperation Agreement with Kent Lake entities and Benjamin Natter under which they will vote their shares with the board’s recommendations, are subject to standstill restrictions, and are limited to beneficially owning no more than 4.99% of the company’s voting securities. The agreement runs until shortly before the 2027 nomination deadline or until January 11, 2027, providing a defined period of voting alignment and reduced potential for proxy contests.
Inogen, Inc. announced a leadership transition and new executive hires while reaffirming its first quarter and full-year 2026 financial outlook. Jason Richardson will become Executive Vice President, Chief Financial Officer and Treasurer on April 6, 2026, succeeding Michael Bourque, who will remain as a senior advisor through June 30, 2026.
Richardson’s employment agreement includes a $525,000 annual base salary, a 70% target bonus, $100,000 in cash sign-on and retention bonuses, and equity awards covering 200,000 shares split between time-based and performance-based restricted stock units, with potential overachievement up to 150,000 PSUs. The agreement provides severance and COBRA-related benefits if he is terminated without cause or resigns for good reason, with enhanced salary continuation during a defined change-of-control period.
Inogen also appointed Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and recently added Corey Moritz as Vice President, U.S. Business to Business Sales. The company highlights these appointments as supporting its next phase of growth and notes continued use of its investor relations website for material disclosures.
Inogen, Inc. reported modest growth but sharply better profitability for 2025 and announced a new share repurchase program. Full-year 2025 revenue rose 3.9% to $348.7 million, driven by 18.4% growth in international sales, while U.S. sales and rentals declined.
Net loss narrowed to $22.7 million from $35.9 million, and adjusted EBITDA turned positive at $2.7 million versus a $9.5 million loss in 2024. Cash, marketable securities, and restricted cash totaled $120.9 million with no debt. The board authorized a share repurchase program of up to $30 million through December 31, 2027.
For 2026, Inogen expects revenue of $366–$373 million, about 6% growth at the midpoint, and remains focused on further adjusted EBITDA improvement. Management highlighted new product launches, a strong balance sheet, and a strategic collaboration in China as key supports for future growth.
Inogen, Inc. filed a current report to let investors know it has released preliminary, unaudited revenue results for its fourth quarter and full year ended December 31, 2025. The company communicated these figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. The filing emphasizes that the amounts are preliminary, have not been audited, and may change once the annual financial statements are completed, so they provide only a partial view of the company’s financial performance. Inogen also clarifies that the press release and related information are being furnished, not filed, which affects how they are treated under securities laws and in future SEC filings.
Inogen, Inc. (INGN) furnished a press release with Q3 2025 results. The company submitted an 8‑K under Item 2.02 to provide its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is dated November 5, 2025.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act. An Inline XBRL cover page is included as Exhibit 104. The report was signed by Michael Bourque, Executive Vice President, Chief Financial Officer and Treasurer.